Keele Research Repository

Article

Alabas, OA, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Yiu, ZZN, Hampton, PJ, Reynolds, NJ, Owen, CM, Bewley, A, Laws, PM, Warren, RB, Lunt, M, Smith, CH and Griffiths, CEM (2023) Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. British Journal of Dermatology.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Burden, AD, Barker, JNWN, Lunt, M, Ali, H, Kleyn, CE, McElhone, K, Soliman, MM, Green, AC, Griffiths, CEM, Reynolds, NJ and Ormerod, AD (2021) Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Hampton, PJ, Reynolds, NJ, Smith, CH, Lunt, M, Griffiths, CEM and Warren, RB (2020) Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatology.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Hampton, PJ, Reynolds, NJ, Smith, CH, Lunt, M, Griffiths, CEM and Warren, RB (2020) Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 183 (2). 294 - 302.

Pan, S, Tsakok, T, Dand, N, Lonsdale, DO, Loeff, FC, Bloem, K, de Vries, A, Baudry, D, Duckworth, M, Mahil, S, Pushpa-Rajah, A, Russell, A, Alsharqi, A, Becher, G, Murphy, R, Wahie, S, Wright, A, Griffiths, CEM, Reynolds, NJ, Barker, J, Warren, RB, David Burden, A, Rispens, T, Standing, JF, Smith, CH and Study Group, the BSTOP Study Group, the PSORT Consortium, BADBIR (2020) Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. Clinical and Translational Science, 13 (2). 400 - 409.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Williams, S, Yiu, ZZN, McElhone, K, Ashcroft, DM, Kleyn, CE, Jabbar-Lopez, ZK, Owen, CM, Reynolds, NJ, Smith, CH, Wilson, N, Warren, RB and Griffiths, CEM (2019) Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology, 181 (2). 256 - 264.

Dand, N, Duckworth, M, Baudry, D, Russell, A, Curtis, CJ, Lee, SH, Evans, I, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Alsharqi, A, Becher, G, Burden, AD, Goodwin, RG, McKenna, K, Murphy, R, Perera, GK, Rotarescu, R, Wahie, S, Wright, A, Reynolds, NJ, Warren, RB, Griffiths, CEM, Smith, CH, Simpson, MA, Barker, JN, Study Group, BADBIR, Study Group, BSTOP and Consortium, PSORT (2018) HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143 (6). 2120 - 2130.

Warren, RB, Marsden, A, Tomenson, B, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Soliman, MM, Burden, AD, Reynolds, NJ, Stocken, D, Emsley, R, Griffiths, CEM, Smith, C, Consortium, PSORT and Study Group, BADBIR (2018) Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180 (5). 1069 - 1076.

Yiu, ZZN, Ashcroft, DM, Evans, I, McElhone, K ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, Smith, CH, Walton, S, Murphy, R, Reynolds, NJ, Ormerod, AD, Griffiths, CEM, Warren, RB and Study Group, BADBIR (2018) Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180 (2). 329 - 337.

Iskandar, IYK, Warren, RB, Lunt, M, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Evans, I, McElhone, K, Smith, CH, Reynolds, NJ, Ashcroft, DM, Griffiths, CEM and Study Group, BADBIR (2017) Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138 (4). 775 - 784.